Health Tech & Medtech · Paris, France · Founded 2018
Nabla is a technology company specializing in artificial intelligence for the healthcare sector, providing an ambient AI assistant to streamline clinical workflows and reduce administrative burdens for medical practitioners. Founded in Paris, France, in 2018 by CEO Alexandre Lebrun, COO Delphine Groll, and CTO Martin Raison, the company was established to address the significant administrative workload that contributes to clinician burnout. Lebrun is a serial entrepreneur with a background in AI, having previously founded and sold two other AI companies, Wit.ai to Facebook and VirtuOz to Nuance Communications.
The company's core product, Nabla Copilot, is an AI-powered assistant that transcribes doctor-patient conversations in real-time to automatically generate structured and comprehensive clinical notes. This system is designed to seamlessly integrate with major Electronic Health Records (EHRs) such as Epic, Cerner, and athenahealth, saving physicians significant time on documentation. The platform supports over 55 specialties and 35 languages and offers extensive customization options to fit individual clinician preferences. To develop its models, Nabla initially operated its own virtual clinics to gather consented patient conversation data, which helped refine its AI.
Nabla operates on a business model that includes a subscription service for individual clinicians, priced at $119 per month after a free trial, and enterprise-level contracts with healthcare organizations. Its clients include a range of healthcare providers from large health systems and academic medical centers to digital health companies and physician groups. As of mid-2025, over 85,000 clinicians and 130 healthcare organizations were using Nabla's technology. The company has demonstrated significant growth, with a reported fivefold increase in revenue over a six-month period.
The company is expanding its capabilities beyond documentation to become a more comprehensive agentic AI platform. Future developments include a real-time coding assistant to flag billing issues, tools for nurses and inpatient teams, and the ability to initiate actions within the EHR. In 2024, KLAS Research recognized Nabla for its customizable, intuitive, and accurate ambient AI assistant.
Nabla has successfully raised a total of $120 million in funding. A Series B round in January 2024 brought in $24 million, followed by a $70 million Series C round in June 2025. Key investors include HV Capital, Highland Europe, Cathay Innovation, and Tony Fadell's Build Collective. Noted AI researcher Yann LeCun is also an investor and advisor to the company.
Keywords: ambient AI, clinical documentation, medical scribe, healthcare AI, natural language processing, clinical workflow automation, EHR integration, physician burnout, medical transcription, clinical notes, AI assistant, health tech, medical coding AI, real-time documentation, patient encounter summary, voice-enabled AI, generative AI, healthcare administration, clinical intelligence, agentic AI
Dealroom maps Nabla's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
24team members profilednamed & role-tagged by Dealroom
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Market sentiment
What the market is saying about Nabla
An AI-synthesized read of the highest-engagement posts about Nabla on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nabla on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.